Proactive Investors - Run By Investors For Investors

Recce to reveal submission details from FDA

The halt will remain in place until Thursday 16th November 2017.
Recce to reveal submission details from FDA
The company's shares are in pre-open

Recce Ltd (ASX:RCE) has been granted a trading halt by the ASX pending the receipt of information from the United States Food and Drug Administration (FDA) following Recce’s recent data submission.

Recce is focused on the development of a new class of synthetic antibiotics.

The halt will remain in place until the opening of trade on Thursday 16th November 2017, or earlier if an announcement is made to the market.

View full RCE profile View Profile

Recce Ltd Timeline

Related Articles

tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
Dog skeleton with cannabis plant leaf
July 16 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use